The August 2026 edition of the 1Cell.Ai Newsletter explores a critical shift in precision oncology: moving beyond diagnosis by morphology and beyond genomics alone to understand the complete biology of cancer. This issue examines why a single biopsy, mutation profile,...
The July 2026 edition of the 1Cell.Ai Newsletter explores a pivotal moment in precision oncology, when emerging evidence becomes clinical practice. This issue unpacks the latest NCCN Bladder Cancer guideline update endorsing ctDNA-based minimal residual disease (MRD) testing for treatment...
ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell.Ai June 2026 Edition Newsletter captures why. From landmark trial data reshaping treatment sequencing to a deeper understanding of how tumours evolve resistance in real time, this month’s research...